Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment.

Donovan JL., Hamdy FC., Lane JA., Young GJ., Metcalfe C., Walsh EI., Davis M., Steuart-Feilding T., Blazeby JM., Avery KNL., Martin RM., Bollina P., Doble A., Doherty A., Gillatt D., Gnanapragasam V., Hughes O., Kockelbergh R., Kynaston H., Paul A., Paez E., Powell P., Rosario DJ., Rowe E., Mason M., Catto JWF., Peters TJ., Wade J., Turner EL., Williams NJ., Oxley J., Staffurth J., Bryant RJ., Neal DE.

Outcomes after Localized Prostate Cancer TreatmentDonovan et al. present the long-term patient-reported outcomes of 1643 randomly assigned participants in the ProtecT (Prostate Testing for Cancer and Treatment) trial. Functional and quality-of-life impacts of prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring are described. Over the trial period from 7 to 12 years, generic quality-of-life scores were similar among all groups, with varying degrees of impact on urinary leakage, sexual function, and fecal leakage depending on the treatment group.

DOI

10.1056/EVIDoa2300018

Type

Journal article

Journal

NEJM Evid

Publication Date

04/2023

Volume

2

Keywords

Male, Humans, Prostatic Neoplasms, Androgen Antagonists, Treatment Outcome, Quality of Life, Patient Reported Outcome Measures

Permalink Original publication